A milestone the AI-in-medicine field has promised for a decade is now in sight. Insilico Medicine’s Rentosertib, a drug whose target and molecule were both identified by AI, has begun Phase III trials for idiopathic pulmonary fibrosis, the final stage before regulators decide whether it becomes medicine. The X posts calling it an “AI-only discovered drug” oversimplify; the precise claim is remarkable enough.
Rentosertib’s TNIK target was proposed by Insilico’s discovery platform and the molecule generated by its chemistry models, with humans running the trials that every drug must pass. The company also announced a collaboration with Takeda this month worth up to roughly $600 million in upfront and milestone payments.
Why Phase III is the line that matters
Plenty of AI-designed molecules have entered Phase I, which mostly tests safety. Phase III tests whether the drug actually works at scale, and it is where most drugs die. As a physician, this is the first checkpoint I would call decisive: pass it, and AI drug discovery stops being a promising method and becomes a validated one. The economics of health AI’s funding boom are, in a real sense, priced on trials like this one.
The honest caveat
IPF is a graveyard for hopeful compounds; existing therapies slow decline rather than reverse it. A Phase III initiation is a bet, not a result, and readouts are years away. What has already changed is the timeline: target-to-Phase-III in this timeframe is dramatically faster than the industry’s decade-plus norm, and that speed advantage survives even if this particular molecule fails.
What to watch
Watch enrollment pace, any interim analyses, and whether other AI-native drugs follow into late-stage trials this year. One success reprices the whole category; so would one high-profile failure. For how the field works end to end, see our physician’s explainer on AI drug discovery.
AI and business tech news, verified by a physician who reads the filings. One email a week, no noise.
